Log in

Clinuvel Pharmaceuticals Stock Price, News & Analysis (ASX:CUV)

-1.84 (-5.08 %)
(As of 10/15/2019 02:36 AM ET)
Today's Range
Now: A$34.41
50-Day Range
MA: A$27.20
52-Week Range
Now: A$34.41
Volume422,002 shs
Average VolumeN/A
Market Capitalization$1.68 billion
P/E Ratio94.02
Dividend Yield0.07%
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited is headquartered in Melbourne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9660 4900



Sales & Book Value

Annual Sales$31.05 million
Cash FlowA$1.04 per share
Book ValueA$1.17 per share



Market Cap$1.68 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive CUV News and Ratings via Email

Sign-up to receive the latest news and ratings for CUV and its competitors with MarketBeat's FREE daily newsletter.

Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions

What is Clinuvel Pharmaceuticals' stock symbol?

Clinuvel Pharmaceuticals trades on the ASX under the ticker symbol "CUV."

Has Clinuvel Pharmaceuticals been receiving favorable news coverage?

Headlines about CUV stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clinuvel Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Clinuvel Pharmaceuticals.

Who are some of Clinuvel Pharmaceuticals' key competitors?

What other stocks do shareholders of Clinuvel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Worldpay (WP), REA Group (REA), CSL (CSL), Cochlear (COH) and Afterpay Touch Group (APT).

Who are Clinuvel Pharmaceuticals' key executives?

Clinuvel Pharmaceuticals' management team includes the folowing people:
  • Dr. Philippe Jacques Wolgen, CEO, MD & Director (Age 56)
  • Mr. Darren M. Keamy, CFO & Company Sec. (Age 46)
  • Dr. Dennis J. Wright BPharm, M.Sc., Ph.D., Acting Chief Scientific Officer
  • Lachlan Hay, Gen. Mang. of Europe

What is Clinuvel Pharmaceuticals' stock price today?

One share of CUV stock can currently be purchased for approximately A$34.41.

How big of a company is Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals has a market capitalization of $1.68 billion and generates $31.05 million in revenue each year. View Additional Information About Clinuvel Pharmaceuticals.

What is Clinuvel Pharmaceuticals' official website?

The official website for Clinuvel Pharmaceuticals is http://www.clinuvel.com/.

How can I contact Clinuvel Pharmaceuticals?

The company can be reached via phone at 61 3 9660 4900.

MarketBeat Community Rating for Clinuvel Pharmaceuticals (ASX CUV)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  40
MarketBeat's community ratings are surveys of what our community members think about Clinuvel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CUV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel